PHP Code

Using the PHP code extracts allows Academic Staff Profiles to be displayed in a number of different styles including the tabbed format shown below - the data is provided dynamically from the IRIS application, while maintaning the consistent look and feel of your site.

Prof Hans Stauss

  • Extension:

    #6 292 x33321

  • Email:

    h.stauss@ucl.ac.uk

  • Appointments:

    Professor of Tumour Imunology, Research Department of Immunology, Div of Infection & Immunity

Research Summary

The main focus of our work is the analysis of antigen-specific T lymphocyte responses to tumours and the development of immunotherapy approaches for cancer treatment. The transfer of T cell receptor (TCR) genes provides an exciting strategy to equip patient T lymphocytes with well-characterized TCRs, allowing the gene modified T cells to attack tumour cells. We also use the TCR transfer approach to explore whether it can control EBV associated malignancies and CMV spread in immunosuppressed individuals. Our experimental platform involves extensive in vitro analysis of target antigen expression and the definition of effective T cell responses. We use in vivo murine models to test safety and efficacy of new immunotherapy protocols, and are currently translating our research into phase I/II clinical trials with the goal of establishing effective immunity in patients.

Research Activities

  • Effect of Tumour Biology on Therapeutic Response
  • Gene and Cellular Therapy of Haematological Malignancies
  • Genome aberrations in Haematological Malignancies
  • Transplantation Biology

Recent Publications

Displaying 50 most recent publications. For the full list please visit UCL Discovery

  1. Depner M,Wanders J,Stauss H,Jansson A,Dueckers G,Niehues T,Baumann U,Pedersen AS,Kilic SS,Atkinson TP,Puck JM,Franco JL,Devlin L,Jensen TD,Henderson P,Matthijs G,Ben Shoshan M,McCusker C,Jacob CM,Grimbacher B (2012) Gain-of-function mutations in STAT1: A new molecular cause for patients with chronic mucocutaneous candidiasis MYCOSES, 55, 319 - 319.
  2. Uttenthal BJ,Chua I,Morris EC,Stauss HJ (2012) Challenges in T cell receptor gene therapy. J Gene Med, 14(6), 386 - 399. 10.1002/jgm.2637.
  3. Lopez-Herrera G,Tampella G,Pan-Hammarström Q,Herholz P,Trujillo-Vargas CM,Phadwal K,Simon AK,Moutschen M,Etzioni A,Mory A,Srugo I,Melamed D,Hultenby K,Liu C,Baronio M,Vitali M,Philippet P,Dideberg V,Aghamohammadi A,Rezaei N,Enright V,Du L,Salzer U,Eibel H,Pfeifer D,Veelken H,Stauss H,Lougaris V,Plebani A,Gertz EM,Schäffer AA,Hammarström L,Grimbacher B (2012) Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. Am J Hum Genet, 90(6), 986 - 1001. 10.1016/j.ajhg.2012.04.015.
  4. Ghorashian S,Holler A,Flutter B,Xue S-A,Fallah-Arani F,Sivakumaran J,Bennett C,Morris E,Stauss HJ,Chakraverty R (2012) CD4 help can overcome tolerance developing in adoptively-transferred T cells transduced with a self-specific TCR HUMAN GENE THERAPY, 23(5), A6 - A6.
  5. Nicholson E,Ghorashian S,Stauss H (2012) Improving TCR Gene Therapy for Treatment of Haematological Malignancies. Adv Hematol, 2012, 404081. 10.1155/2012/404081.
  6. Zech M,Velica P,Holler A,Chakraverty R,Stauss H (2012) Manipulating mTOR to enhance T cell mediated tumour immunity in vivo HUMAN GENE THERAPY, 23(5), A16 - A16.
  7. Nicholson E,Ahmadi M,Thomas S,Holler A,Carpenter B,Xue SA,Stauss H,Morris E (2012) Enhancing the efficacy of T cell receptor (TCR) gene therapy by co-transfer of TCR and additional CD3 molecules into CD4+T cells BRITISH JOURNAL OF HAEMATOLOGY, 157, 87 - 87.
  8. Chua I,Xue SA,Holler A,Maniusyte R,Zamoyska R,Stauss HJ,Morris EC (2012) Exploiting CD8 beta mutations which increase TCR avidity to improve the function of genetically modified T cells for immunotherapy BRITISH JOURNAL OF HAEMATOLOGY, 157, 87 - 87.
  9. Lopez-Herrera G,Tampella G,Baronio M,Vitali M,Lougaris V,Plebani A,Pan-Hammarstroem Q,Hammarstroem L,Du L,Hultenby K,Trujillo-Vargas CM,Phadwal K,Simon AK,Moutschen M,Etzioni A,Srugo AMI,Melamed D,Liu C,Philippet P,Dideberg V,Aghamohammadi A,Rezai N,Enright V,Stauss H,Herholz P,Salzer U,Eibel H,Pfeifer D,Velkeen H,Gertz EM,Schaeffer AA,Grimbacher B (2012) Mutations in LRBA are Associated with a Syndrome of Immune Deficiency and Autoimmunity JOURNAL OF CLINICAL IMMUNOLOGY, 32(2), 363 - 364.
  10. Field A-C,Stauss HJ,Morris EC,Qasim W (2012) Comparison on lentiviral and Sleeping Beauty transposon-mediated gene expression of T cell receptor genes HUMAN GENE THERAPY, 23(5), A10 - A11.
  11. Simpson AA,Mohammed F,Salim M,Tranter A,Rickinson AB,Stauss HJ,Moss PA,Steven NM,Willcox BE (2011) Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction. Proc Natl Acad Sci U S A, 108(52), 21176 - 21181. 10.1073/pnas.1108422109.
  12. Gehring AJ,Xue SA,Ho ZZ,Teoh D,Ruedl C,Chia A,Koh S,Lim SG,Maini MK,Stauss H,Bertoletti A (2011) Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol, 55(1), 103 - 110. 10.1016/j.jhep.2010.10.025.
  13. Nicholson E,Ahmadi M,Thomas S,Holler A,Carpenter B,Xue SA,Stauss H,Morris E (2011) Enhancing the efficacy of T cell receptor (TCR) gene therapy by co-transfer of TCR and additional CD3 molecules into CD4+T cells HUM GENE THER, 22(10), A119 - A119.
  14. Xue SA,Gao L,Ahmadi M,Ghorashian S,Pospori C,Holler A,Thomas S,Morris E,Stauss HJ (2011) Generation of MHC-I restricted CD4+CMV and EBV specific T cells for the management of leukaemia patients HUM GENE THER, 22(10), A73 - A73.
  15. Chua I,Holler A,Xue SHA,Zamoyska R,Stauss HJ,Morris EC (2011) T cells expressing genetically modified CDS co-receptor have enhanced T cell effector function HUM GENE THER, 22(10), A34 - A35.
  16. Wright GP,Stauss HJ,Ehrenstein MR (2011) Therapeutic potential of Tregs to treat rheumatoid arthritis. Semin Immunol, 23(3), 195 - 201. 10.1016/j.smim.2011.07.004.
  17. Xue S,Gao L,Ghorashian S,Pospori C,Ahmadi M,Holler A,Thomas S,Stauss HJ (2011) GENERATION OF MHC-I RESTRICTED CD4+CMV SPECIFIC T CELLS FOR THE MANAGEMENT OF LEUKEMIA PATIENTS EXPERIMENTAL HEMATOLOGY, 39(8), S65 - S66.
  18. Ahmadi M,King JW,Xue SA,Voisine C,Holler A,Wright GP,Waxman J,Morris E,Stauss HJ (2011) CD3 limits the efficacy of TCR gene therapy in vivo. Blood, 118(13), 3528 - 3537. 10.1182/blood-2011-04-346338.
  19. Pospori C,Xue SA,Holler A,Voisine C,Perro M,King J,Fallah-Arani F,Flutter B,Chakraverty R,Stauss HJ,Morris EC (2011) Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination BLOOD, 117(25), 6813 - 6824. 10.1182/blood-2010-08-304568.
  20. Thomas S,Xue SA,Bangham CR,Jakobsen BK,Morris EC,Stauss HJ (2011) Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen. Blood, 118(2), 319 - 329. 10.1182/blood-2010-12-326736.
  21. Chan HW,Aslam A,Lee CH,Jones L,Wynne K,Wright G,Crack L,McPherson T,Stauss H,Price DR,Ogg GS (2011) Antigen dose and keratinocyte antigen presentation are specific determinants of T cell function in atopic eczema AUSTRALAS J DERMATOL, 52, 19 - 20.
  22. Alpizar YA,Chain B,Collins MK,Greenwood J,Katz D,Stauss HJ,Mitchison NA (2011) Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies. Cancer Immunol Immunother, 60(8), 1127 - 1135. 10.1007/s00262-011-0985-7.
  23. Cellerai C,Harari A,Stauss H,Yerly S,Geretti AM,Carroll A,Yee T,Ainsworth J,Williams I,Sweeney J,Freedman A,Johnson M,Pantaleo G,Kinloch-de Loes S (2011) Early and Prolonged Antiretroviral Therapy Is Associated with an HIV-1-Specific T-Cell Profile Comparable to That of Long-Term Non-Progressors PLOS ONE, 6(4). 10.1371/journal.pone.0018164.
  24. Nicholson EK,Ahmadi M,Thomas S,Carpenter B,Voisine C,Xue S,Stauss HJ,Morris EC (2011) Improving the function of TCR gene modified T-cells for adoptive immunotherapy: co-transfer of additional CD3 molecules enhances functional avidity of TCR-transduced CD4+ T-cells BONE MARROW TRANSPLANTATION, 46, S323 - S323.
  25. Wright GP,Ehrenstein MR,Stauss HJ (2011) Regulatory T-cell adoptive immunotherapy: potential for treatment of autoimmunity. Expert Rev Clin Immunol, 7(2), 213 - 225. 10.1586/eci.10.96.
  26. Ghorashian S,Nicholson E,Stauss HJ (2011) T cell gene-engineering to enhance GVT and suppress GVHD. Best Pract Res Clin Haematol, 24(3), 421 - 433. 10.1016/j.beha.2011.05.004.
  27. Cellerai C,Harari A,Stauss H,Yerly S,Geretti AM,Carroll A,Yee T,Ainsworth J,Williams I,Sweeney J,Freedman A,Johnson M,Pantaleo G,Kinloch-de Loes S (2011) Prolonged antiretroviral therapy initiated at seroconversion is associated with a polyfunctional HIV-1-specific T-cell profile comparable to that of long-term non-progressors (LTNPs) HIV MED, 12, 11 - 11.
  28. Ahmadi M,King J,Xue S-A,Voisine C,Holler A,Wright G,Waxman J,Morris E,Stauss H (2011) CD3 limits the efficacy of TCR gene therapy in vivo IMMUNOLOGY, 135, 53 - 53.
  29. Ahmadi M,King J,Nicholson E,Xue SA,Morris E,Stauss H (2010) Co-transfer of CD3 molecules enhances the anti-tumour responses of TCR-transduced T cells IMMUNOLOGY, 131, 176 - 177.
  30. Gehring AJ,Xue SA,Ho ZZ,Teoh DYL,Ruedl C,Chia A,Koh S,Lim SG,Maini MK,Stauss H,Bertoletti A (2010) ENGINEERING VIRUS-SPECIFIC T CELL IMMUNITY TO TARGET CHRONIC HEPATITIS B VIRUS INFECTION AND HBV-RELATED HEPATOCELLULAR CARCINOMA JOURNAL OF HEPATOLOGY, 52, S40 - S40.
  31. Xue SA,Ghorashian S,Pospori C,Ahmadi M,Holler A,Thomas S,Stauss HJ (2010) Development of CMV-specific T cells for the management of transplantation patients HUMAN GENE THERAPY, 21(10), 1422 - 1423.
  32. Ahmadi M,King J,Nicholson E,Morris E,Stauss H (2010) Enhancing the Efficacy of TCR Gene Therapy by Co-Transfer of CD3 Molecules HUMAN GENE THERAPY, 21(10), 1414 - 1414.
  33. Pospori C,Xue SA,Holler A,Voisine C,Perro M,Fallah-Arani F,Flutter B,Chakraverty R,Stauss HJ,Morris EC (2010) Specificity for a tumor-associated self-antigen drives the development of functional memory T cells in the absence of vaccination HUMAN GENE THERAPY, 21(10), 1365 - 1366.
  34. Morris EC,Martinez-Davila I,Cellerai C,Chen F,Moss P,Khwaja A,Virchis A,Kottaridis P,Stauss HJ (2010) WT1 peptide vaccination in poor risk adult AML patients induces WT1-specific immune responses: Results of a leukaemia research supported phase I clinical trial, WTPV-001 BRITISH JOURNAL OF HAEMATOLOGY, 149, 16 - 16.
  35. Uttenthal BJ,Wright GP,Holler A,Stauss HJ,Chakraverty R,Ec M (2010) Adoptive Therapy with Redirected Antigen-Specific Primary Regulatory T Cells Is a Potential Novel Cellular Therapy for Graft-Versus-Host Disease HUMAN GENE THERAPY, 21(4), 510 - 510.
  36. Field AC,Stauss HJ,Goulden N,Morris E,Qasim W (2010) Defining an Optimal Promoter for Lentiviral Gene Expression of T Cell Receptor Genes HUMAN GENE THERAPY, 21(4), 509 - 510.
  37. Ahmadi M,King J,Nicholson E,Morris E,Stauss H (2010) Enhancing the Efficacy of TCR Gene Therapy by Co-Transfer of CD3 Molecules HUMAN GENE THERAPY, 21(4), 516 - 517.
  38. Perro M,Tsang J,Xue SA,Escors D,Cesco-Gaspere M,Pospori D,Gao L,Hart D,Collins M,Stauss H,Morris EC (2010) Lentiviral Vectors for TCR Gene Transfer: Improved Function of TCR-Transduced T Cells After Non-Activating Cytokine-Mediated Transduction HUMAN GENE THERAPY, 21(4), 512 - 512.
  39. Perro M,Tsang J,Xue SA,Escors D,Cesco-Gaspere M,Pospori C,Gao L,Hart D,Collins M,Stauss H,Morris EC (2010) Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer. Gene Ther, 17(6), 721 - 732. 10.1038/gt.2010.4.
  40. Thomas S,Stauss HJ,Morris EC (2010) Molecular immunology lessons from therapeutic T-cell receptor gene transfer IMMUNOLOGY, 129(2), 170 - 177. 10.1111/j.1365-2567.2009.03227.x.
  41. Pospori C,Xue SA,Holler A,Stauss HJ (2010) Adoptive immunotherapy with TCR-transferred lymphocytes HUMAN GENE THERAPY, 21(10), 1379 - 1379.
  42. Xue SA,Gao L,Pospori C,Ahmadi M,Holler A,Thomas S,Stauss HJ (2010) Development of Virus Specific T Cells for the Management of Leukaemia Patients HUMAN GENE THERAPY, 21(4), 510 - 510.
  43. Chua I,Holler A,Zamoyska R,Stauss H,Morris E (2010) Improving T Cell Functional Avidity Through CD8 Co-Receptor Modification: A Novel Mechanism to Enhance TCR Gene Therapy HUMAN GENE THERAPY, 21(4), 522 - 522.
  44. Wright GP,Notley CA,Uttenthal BJ,Xue SA,Ehrenstein MR,Stauss HJ (2010) Treating Immunopathology with Antigen-Specific Regulatory T Cells Generated by T Cell Receptor Gene Transfer HUMAN GENE THERAPY, 21(4), 499 - 499.
  45. Zech M,Holler A,Stauss H (2010) Overcoming tumour associated T cell inhibition by Indoleamine-2,3-dioxygenase and Arginase I IMMUNOLOGY, 131, 78 - 78.
  46. Wright GP,Notley CA,Xue SA,Bendle GM,Holler A,Schumacher TN,Ehrenstein MR,Stauss HJ (2009) Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci U S A, 106(45), 19078 - 19083. 10.1073/pnas.0907396106.
  47. Pospori C,Cesco-Gaspere M,Xue S,Voisine C,Perro M,Holler A,Wright G,Stauss H,Morris E (2009) WT1-TCR gene transfer into haematopoietic stem cells: a tumour immunotherapy model BONE MARROW TRANSPLANTATION, 43, S72 - S72.
  48. King JW,Thomas S,Corsi F,Gao L,Dina R,Gillmore R,Pigott K,Kaisary A,Stauss HJ,Waxman J (2009) IL15 can reverse the unresponsiveness of Wilms' tumor antigen-specific CTL in patients with prostate cancer. Clin Cancer Res, 15(4), 1145 - 1154. 10.1158/1078-0432.CCR-08-1821.
  49. Dai MS,Nitcheu-Tefit J,Alcock S,Ramirez-Jimenez F,Chao TY,Baril P,Rocha M,Brett SJ,Stauss HJ,Vassaux G (2009) Development of an Escherichia coli expressing listeriolysin-O vaccine against Wilms tumor gene 1-expressing tumors. J Immunother, 32(8), 845 - 855. 10.1097/CJI.0b013e3181aee259.
  50. Cesco-Gaspere M,Morris E,Stauss HJ (2009) Immunomodulation in the treatment of haematological malignancies Clinical and Experimental Medicine, 9(2), 81 - 92.

Qualifications

  • 1987: Doctor of Philosophy, University of Chicago
  • 1982: Doctor of Medicine, Albert-Ludwigs-Universität Freiburg